Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
Journal
Oncotarget
Journal Volume
8
Journal Issue
12
Pages
19057-19064
Date Issued
2017
Author(s)
Abstract
This retrospective cohort study evaluated the risk of prostate cancer associated with sitagliptin use in Taiwanese male patients with type 2 diabetes mellitus by using the reimbursement databases of the National Health Insurance. Male patients with newly diagnosed type 2 diabetes mellitus at an age ?25 years between 1999 and 2010 were recruited. A total of 37,924 ever users of sitagliptin and 426,276 never users were followed until December 31, 2011. The treatment effect of sitagliptin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Analyses were also conducted in a 1:1 matched pair cohort based on 8 digits of propensity score. Results showed that during follow-up, 84 ever users and 2,549 never users were diagnosed of prostate cancer, representing an incidence of 140.74 and 240.17 per 100,000 person-years, respectively. The hazard ratio (95% confidence intervals) for ever users versus never users was 0.613 (0.493- 0.763). The respective hazard ratio for the first, second, and third tertile of cumulative duration of sitagliptin use < 5.9, 5.9-12.7 and > 12.7 months was 0.853 (0.601-1.210), 0.840 (0.598-1.179) and 0.304 (0.191-0.483), respectively; and was 0.856 (0.603- 1.214), 0.695 (0.475-1.016) and 0.410 (0.277-0.608) for cumulative dose < 15,000, 15,000-33,600 and > 33,600 mg, respectively. Findings were supported by analyses in the matched cohort. In conclusion, sitagliptin significantly reduces the risk of prostate cancer, especially when the cumulative duration is > 12.7 months or the cumulative dose > 33,600 mg.
Subjects
Incretin; National Health Insurance; Prostate cancer; Sitagliptin; Taiwan
SDGs
Other Subjects
sitagliptin; antidiabetic agent; sitagliptin; adult; Article; cancer incidence; cancer risk; cohort analysis; controlled study; follow up; hazard ratio; human; major clinical study; male; non insulin dependent diabetes mellitus; probability; propensity score; prostate cancer; retrospective study; risk reduction; Taiwanese; treatment duration; aged; Diabetes Mellitus, Type 2; incidence; middle aged; proportional hazards model; Prostatic Neoplasms; Taiwan; Adult; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Sitagliptin Phosphate; Taiwan
Publisher
Impact Journals LLC
Type
journal article